VolitionRx Partners with Werfen for Innovative APS Diagnostics

On September 9, 2025, VolitionRx Limited (NYSE AMERICAN: VNRX), an innovative player in the field of epigenetics, entered into a strategic partnership with Werfen's Immunoassay Technology Center, a recognized leader in specialized diagnostics. This collaboration marks an exciting phase in the quest for advanced diagnostic solutions for Antiphospholipid Syndrome (APS).

Understanding Antiphospholipid Syndrome (APS)

Antiphospholipid Syndrome is a complex autoimmune disorder characterized by an increased risk of blood clotting, affecting approximately four million individuals globally. The syndrome raises the likelihood of severe complications, such as stroke, heart attack, and recurrent pregnancy losses. Diagnosing APS is intricate, relying on multiple blood tests that can confirm the presence of specific antibodies, necessitating thorough long-term monitoring.

The Significance of the Collaboration

This new agreement entails Volition granting Werfen research licensing and exclusive commercial rights to its proprietary Nu.Q® NETs test associated with APS. According to Gael Forterre, Chief Commercial Officer of Volition, this partnership signifies the company's commitment to leverage its expertise in epigenetics through established diagnostic companies for better patient outcomes.

Werfen will assess the clinical utility of the Nu.Q® H3.1 NETs assay within their trusted platforms. They also have the option to negotiate favorable terms for commercializing this groundbreaking product, enhancing its testing portfolio for APS.

Marta Palicio, Werfen's Innovation RD Director, remarked positively on the collaboration, highlighting early successes in detecting neutrophil extracellular traps (NETs) in APS patients. Their ongoing investigations aim to validate NETs' role in managing APS, representing a significant improvement in diagnostic strategy.

Future Implications

The collaboration holds the promise of providing better tools to monitor APS effectively, aiming to personalize patient care. Emerging research indicates that targeting NET pathways could open new therapeutic avenues for managing thrombotic complications associated with APS, making this collaboration particularly timely.

Remi Rabeuf from Volition emphasized the potential of the Nu.Q® NETs test as a cost-effective means to monitor APS patients continuously throughout their lives. This partnership not only signifies a major milestone for Volition but could ultimately improve treatment pathways for APS, fostering better quality of life for patients.

A Look Ahead

As both Volition and Werfen strengthen their collaboration, the promise of innovation in the diagnostics landscape grows. The ongoing partnership is set to transform how APS is managed, potentially leading to a diagnostic breakthrough that aligns well with Volition's mission to enhance early detection and continuous monitoring of life-altering diseases.

In summary, this strategic alliance between VolitionRx and Werfen showcases a bright future for both companies in the realm of specialized diagnostics, emphasizing shared goals to enhance patient outcomes through innovative technology and collaborative efforts.